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AbstrAct:
The invasive phenotype of glioblastoma multiforme (GBM) is a hallmark of malignant 
process, yet the molecular mechanisms that dictate this locally invasive behavior 
remain poorly understood. Over-expression of PIAS3 effectively changes cell shape 
and inhibits GBM cell migration. We focused on the molecular target(s) of PIAS3 
stimulated sumoylation, which play an important role in the inhibition of GBM cell 
motility. Here we report, through the immunoprecipitation with SUMO1 antibody, 
followed by proteomic analysis, the identification of vimentin (vimentin354), a nuclear 
component in GBM cells, as the main target of sumoylation promoted by PIAS3.
INtrODUctION
Glioblastoma multiforme (GBM) represents 29% 
of all primary brain tumors or 5,000 new cases per year 
in the United States [1]. The infiltrative growth pattern 
of  these  tumors  precludes  curative  neurosurgery  and 
no  therapeutic  modality  has  substantially  changed  the 
outcome of patients with GBM [2]. GBM spread by active 
cell  migration  rather  than  by  passive,  hematogenous 
spread [3-5]. A main characteristic of GBM is the cells’ 
extreme  migration  potential  and  topographical  diffuse 
nature,  resulting  in  the  inability  to  completely  dissect 
GBM tumors [6]. New effective therapeutic modalities 
for advanced and invasive GBM are desperately needed.
Protein Inhibitor of Activated STAT3 (PIAS3) was 
first  identified  as  a  specific  inhibitor  by  blocking  the 
DNA-binding activity of STAT3 and inhibiting STAT3-
mediated gene activation [7]. New evidence indicates that 
PIAS3  suppresses  STAT3-mediated  signal  transduction 
by  interacting  with ATBF1  [8].  PIAS3  also  acts  as  a 
binding protein of other transcriptional regulators such 
as androgen receptor, TIF2, and NF-kappaB [9]. Recent 
work has revealed that PIAS3 acts as an E3-like ligase to 
stimulate the attachment of small ubiquitin-like modifier 
(SUMO) to target proteins, which act in such important 
cellular pathways as Wnt signaling, the p53 pathway and 
steroid hormone signaling [9, 10]. 
PIAS3 induces apoptosis in prostate cancer cells 
both in vitro and in vivo [11]. When PIAS3 was over-
expressed in GBM cells, complete suppression of growth 
and  inhibition  of  cell  migration  was  observed  [12]. 
Considering  the  SUMO  ligase  activity  of  PIAS3,  an 
obvious question is whether PIAS3-mediated sumoylation 
of regulators in apoptosis/migration pathways is involved 
in the inhibitory process. To characterize GBM’s extreme 
migration potential, we focused on the effect of PIAS3-
stimulated sumoylation on the inhibition of GBM cell 
migration. Oncotarget 2010; 1:  620 - 627 621 www.impactjournals.com/oncotarget
rEsULts
Ad/PIAs3 inhibit U373 cell migration 
When quiescent GBM U373 cells were infected with 
a low titer (5 pfu/cell) of Ad/PIAS3, the cell’s morphology 
was changed, and cells became rounded and lost processes 
(Figure  1A). As  demonstrated  in  the  “artificial  wound 
assay”, a two-dimensional cell motility system [13], U373 
cell migration was clearly inhibited compared with the 
cells infected by Ad/EGFP (Figure 1A). The inhibition of 
motility can be reflected by decreased cell number (Figure 
1B)  and  reduced  distance  (F  polymerization  at  72ΟC 
for igure 1C) migrated out from the origin of artificial 
wounding. The control cells have long processes toward 
the direction of movement. In contrast, Ad/PIAS-treated 
cells form few, if any, long processes, and such processes 
do not extend in forward direction.
To examine whether PIAS3 promotes sumoylation, 
U373  cells  were  transfected  with  enhanced  green 
fluorescent  protein  (EGFP)-tagged  SUMO1  before 
infection. As shown in Figure 1D, PIAS3 did promote 
accumulation  of  EGFP-SUMO1  fusion  proteins  in 
the  nuclei,  reflected  by  increased  intensity  of  green 
fluorescence in Ad/PIAS3-treated GBM cells. 
PIAs3 promotes Vimentin354 sumoylation 
The next question was what are the molecular 
targets of PIAS3-stimulated sumoylation, which play an 
important role in the inhibition of GBM cell motility. 
The PIAS3 had been mainly localized in nuclei [9, 12] 
and fluorescent EGFP-SUMO1 was accumulated in the 
nucleus upon PIAS3 stimulation. Unlike most sumoylated 
proteins  identified  by  over-expressed  tag-SUMO,  our 
goal  was  to  check  the  stimulatory  effect  of  PIAS3  on 
endogenous SUMO. Then, agarose conjugated SUMO1 
antibody (Santa Cruz) was used for immunoprecipitation 
(IP) of nuclear proteins. As shown in Figure 2B, the two 
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Figure 1. Inhibition of U373 cell migration by Ad/PIAs3. A. Confluent U373 cells were cut and lifted at the origin (arrow), and infected 
with 5 pfu/cell Ad/PIAS3. Images (original magnification × 10 or × 20) of migration were taken by phase contrast microscopy at the times 
indicated. Sizes of images are: 420 × 210 nm for 24 hrs, 420 × 315 nm for 48 hrs, 840 × 630 nm for 72 hrs.Oncotarget 2010; 1:  620 - 627 622 www.impactjournals.com/oncotarget
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Figure 1 b. Number of cells migrated out from the origin; c. Median distances of cells migrated from the origin. Ad/PIAS3 infected cells 
showed a decreased cell number and shorter distance in migration compared with control cells (mean of three independent experiments, 
Student’s t-test P<0.01). 
D
Figure 1 D. PIAS3 promotes sumoylation in U373 cells. Phase-contrast microscopic images collected 24 hours of control (U373), Ad/
PIAS3 infected (+ PIAS3), EGFP-SUMO1 transiently transfected (+ GFP-SUMO), and Ad/PIAS3 infected U373 cells after EGFP-SUMO1 
transfection (+  GFP-SUMO  +  PIAS3).  Fluorescent EGFP-SUMO1  clearly demonstrated that PIAS3  increased SUMO1  expression and 
accumulation of EGFP-SUMO fusion protein in nuclei (lower 2 panels, respectively).Oncotarget 2010; 1:  620 - 627 623 www.impactjournals.com/oncotarget
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Vimentin354(gi:5030431)Matched peptides shown in Bold Red
1 RFANYIDKVR FLEQQNKILL AELEQLKGQG KSRLGDLYEE EMRELRRQVD 
51 QLTNDKARVE VERDNLAEDI MRLREKLQEE MLQREEAEST LQSFRQDVDN 
101 ASLARLDLER KVESLQEEIA FLKKLHEEEI QELQAQIQEQ HVQIDVDVSK 
151 PDSTAALRDV RQQYEIVAAK NLQEAEEWYK SKFADLSEAA NRNNDALRQA 
201 KQESTEYRRQ VQSLTCEVDA LKGTNECLER QMREMEEKFA VEAANYQDTI 
251 GRLQDEIQNM KEEMARHLRE YQDLLNVKMA LDIEIATYRK LLEGEESRIS
301 LPLPNFSSLN LRETNLDSLP LVDTHSKRTL LIKTVETRDG QVINETSQHH 
351 DDLE
Figure 2. Validation of PIAs3 stimulated Vimentin354 sumoylation in the nucleus of U373 cell. A. Representative Nano-HPLC/MS/MS 
analysis for protein identification. The complete vimentine354 peptide sequence is given on the top panel. Middle panel: Nano-HPLC/MS/MS 
base peak chromatogram of the tryptic digests of gel slice in the mass range of 53 kDa; lower panel: MS spectrum at retention time of 63.2 min, 
and MS/MS spectrum of peptide ILLAELEQLK unique to the Vimentin354 protein. Oncotarget 2010; 1:  620 - 627 624 www.impactjournals.com/oncotarget
most prominent proteins, with molecular weights of about 
53 kDa and 86 kDa, can be identified by SUMO antibody 
in  the  Ad/PIAS3-infected  cells,  indicating  that  PIAS3 
indeed  promotes  endogenous  sumoylation  of  nuclear 
proteins. Because of the limited resolution of western 
blot results, we could not detect the presence of more 
sumoylated but less-abundant proteins by SUMO-IP.
Coomassie Blue-stained nuclear IP protein bands 
separated  on  polyacrylamide  gel  were  excised,  and 
protein in gel or the whole IP product on agarose beads 
was trypsinized. Then digested peptides were analyzed 
by  high  performance  liquid  chromatography  and  mass 
spectrometry/mass  spectrometry  (HPLC-MS/MS). 
Surprisingly, the vimentin354 (Accession No. AAA61281) 
[14]  was  identified  in  all  four  independent  SUMO-IP 
followed by MS-MS analysis from two MS cores (Figure 
2A). The molecular weight of vimentin354 is about 41.5 
kDa, when modified by SUMO1 (MW: 11 kDa), should 
move to 52.6 kDa. Western blot with goat anti-vimentin 
antibody confirmed the sumoylation of vimentin354, which 
was only found in the IP product of nuclear lysates (Figure 
2B and C). Vimentin466 (Accession No. NP_003371, MW 
53.6 kDa) was also identified from the band at about 86 
kDa, but failed to be recognized by goat anti-vimentin 
antibody. When the SUMO-IP pulled nuclear proteins 
from different time points were analyzed by western blot, 
vimentin354 was found to decrease with time of Ad/PIAS3 
infection, reducing to undetectable level after 48 hours 
(Figure 2D).
DIsscUssION 
Vimentin has been used as a molecular marker for 
GBM and astrocytomas [15-17]. Gene expression profiles 
assessed from laser capture-micro-dissected GBM cells 
have shown high levels of vimentin in the tumor core 
[18].  Theoretical  analysis  predicted  two  lysines  with 
high probability (K261 and K201), and one lysine with 
low probability (K111) [19] as the putative SUMO site. 
Calculated from the molecular weight on western blot, 
only one SUMO was attached to vimentin354, result in the 
major band on SUMO-IP expected at 53 kDa. Sub-cellular 
localization  of  vimentin354 was predicted to be in the 
nucleus with 76.7% of reliability by theoretical calculation 
[20],  which  matched  our  observation.  Compared  with 
the  abundant  vimentin466 located in both nucleus and 
cytoplasm, the nuclear vimentin354 was expressed at very 
low level, therefore, vimentin354 could not be visualized by 
Figure 2 b & c. Quiescent cells were infected with Ad/PIAS3 for 24 hrs and cytosolic or nuclear protein lysate was prepared. Then 80% of 
the nuclear protein immunoprecipitated by SUMO antibody (nuclear IP) from Ad/EGFP mock control (C) or Ad/PIAS3 (P) infected U373 cells 
were immunoblotted to demonstrate the same motility of both SUMO (b) and vimentin354 (c). Fifty microgram each of cytosolic and nuclear 
proteins was blotted to display the molecular weight of unmodified Vimentin354 at about 41.5 kDa. D. Sumoylation of nuclear vimentin354 at 
different time points after Ad/PIAS3 infection. E. Comparison of vimentin354 and vimentin466. With 91% of homology, each has a filament rod 
domain, essential for protein-protein interaction. Vimentin354 lacks an IF head domain, which is responsible for DNA binding, at the N-terminus.
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fluorescence immunohistochemistry (data not shown). The 
absence of lysine or arginine residues in the C-terminus of 
mammalian SUMO makes it difficult to map sumoylation 
sites [21], which may explain our failure to identify 
SUMO peptide in our MS/MS analysis.
Vimentin,  as  a  primordial  component  of  the 
cytoskeleton  and  the  nuclear  envelope,  belongs  to  the 
class-III intermediate filaments (IF) found in mesenchymal 
cells. The de novo expression of vimentin is frequently 
involved  in  the  epithelial-to-mesenchymal  transition 
(EMT)  associated  with  increased  invasive/migratory 
properties of epithelial and cancer cells [22]. In prostate 
cancer cells, the level of vimentin expression has been 
correlated with cell motility, and the majority of poorly 
differentiated cancers and bone metastases showed high 
vimentin expression in tumor cells [23]. When vimentin 
was experimentally reduced, the cell’s invasive potential 
could  be  effectively  abolished  in  the  in vitro  Matrigel 
invasion  assay  [24].  Over-expression  of  vimentin  in 
breast  cancer  model  leads  to  augmentation  of  motility 
and invasiveness in vitro, which can be transiently down-
regulated by antisense oligonucleotides to vimentin [25]. 
Using  an  in  vitro  wound-healing  model,  it  had  been 
demonstrated that vimentin is transiently associated with, 
and could be functionally involved in the migratory status 
of breast epithelial cells [26]. Our observation hinted that 
sumoylation can be another way of removing functional 
vimentin, leading to the inhibition of GBM cell motility.
Compared  with  vimentin466,  vimentin354  lacks  112 
residues  at  the  N-terminus,  representing  the  IF  head 
(DNA binding) sequence, which is able to alter nuclear 
architecture and chromatin distribution. With 91% 
homology  to  vimentin466  (Figure  2E),  vimentin354 has 
the same B-Box-type zinc finger, zinc-binding domain, 
RING-finger  (Really  Interesting  New  Gene)  domain, 
involved in mediating protein-protein interactions, which 
have a wide range of functions such as signal transduction 
and development. Migration is closely linked to cell shape 
and  to  mechanics  of  the  cytoskeleton.  Other  than  the 
current model of viscous fluid-like cytoplasm and elastic 
membrane to be the major load-bearing elements, the idea 
that “hard-wired” transmembrane receptors, cytoskeleton 
filaments (including vimentin), and nuclear scaffolds are 
responsible for cell shape control had been proposed [27]. 
Vimentin354 may serve as the end connection molecule in 
the nucleus to hold the entire IF network, which is crucial 
for  supporting  the  three-dimensional  shape  of  the  cell 
skeleton.
Post-translational  modification  by  SUMO-1  is  a 
highly conserved process in eukaryotic cells and plays 
important  regulatory  roles  in  many  cellular  processes. 
Since  vimentin354  is  the  major  target  of  endogenous 
sumoylation in the nucleus upon PIAS3 stimulation, it 
may play a key role in maintaining the normal cell shape 
and  motility  of  GBM  cells. Targeting  the  cell  motility 
component actin had been proposed to combat cancer cell 
migration [28]. Our data suggest that vimentin354 may be 
added to the therapeutic target for fighting GBM.
MAtErIALs AND MEtHODs
cell culture and Ad/PIAs3 infection
Glioblastoma U373 cells were cultured in Dulbecco’s 
modified Eagles medium (DMEM) containing 5% fetal 
bovine  serum  and  antibiotics.  Cells  were  incubated  at 
37C  in  a  humidified  atmosphere  containing  5%  CO2. 
Adenovirus5  with  PIAS3  was  constructed.  The  entire 
coding sequence of human PIAS3 (Genbank accession 
number NM_006099) was amplified by RT-PCR, cloned 
into  the  pShuttle-CMV  vector,  and  sent  to  Cleveland 
Clinic Foundation Virus Core for adenovirus construction 
and  purification.  Infection  was  performed  by  diluting 
the  virus  to  the  appropriate  concentration  in  medium. 
Adenovirus5 vector was used as control.
cell count
50,000 U373 cells were seeded in each well of 12-
well tissue culture plate, and infected with 100 pfu/cell 
Ad/PIAS3. Cells were trypsinized at different time points, 
and counted as total cell number or cell survival by trypan 
blue  exclusion.  The  numbers  of  average  and  standard 
error are obtained from triplet wells.
In-gel digestion of sDs-PAGE separated and 
coomassie-stained gel
Coomassie-stained  polyacrylamide  gel  containing 
protein bands of interest were excised. gels were destained 
with 50% acetonitrile in 100 mM ammonium bicarbonate, 
and then 100% acetonitrile. The proteins were reduced 
in  the  gels  with  20  mM  dithiothreitol  (DTT)  at  room 
temperature for 30 min, followed by alkylation with 50 
mM iodoacetamide in 100 mM ammonium bicarbonate 
for  30  min  in  the  dark.  After  treatment,  the  reagents 
were removed and the gel pieces were washed with 100 
mM ammonium bicarbonate and then dehydrated in 
acetonitrile. The dried gel pieces were then rehydrated 
in  a  solution  of  sequencing  grade,  modified  trypsin  in 
50 mM ammonium bicarbonate for digestion overnight. 
Tryptic peptides were extracted from the gel with 50% 
acetonitrile in 5% formic acid. The LC-MS/MS analysis 
is performed on Bruker HCT 3000 plus ESI-IonTrap Mass 
Spectrometer coupled with Agilent 1100 HPLC system. 
An  additional  Shimadzu  LC-10ADvp  HPLC  pump  is 
used for sample loading. Tryptically digested sample is 
injected and first loaded onto a Rheodyne Peptide Captrap 
(Michrom  BioResources,  Inc.),  then  eluted  through  a Oncotarget 2010; 1:  620 - 627 626 www.impactjournals.com/oncotarget
capillary RP-HPLC column (10 cm long, 300 µm ID, 5Å 
C18, from Grace Vydac). The elution gradient is: 2% B for 
10 min; 5%-45% B for 200 min; 45%-85% B for 30min; 
85% B for 30 min. The ion-trap mass spectrometer is set 
in auto ms/ms mode; number of precursor ions is 3. The 
collected MS/MS data are processed (compound finding 
and deconvolution) by Bruker Data Analysis, version 3.1.
Immunohistochemistry
Slides of human normal organs and human various 
tumors were purchased from Imgenex. The paraffin was 
removed by xylene and followed by sequencial ethanol 
wash. Antigens were retrieved by boiling the slides for 5 
minutes in 10 mM Sodium Nitrate (pH 6.0) and rehydrated 
in PBS. The slides were first blotted in PBS with 0.5% BSA 
and 0.2% cold water fish gelatin (PBG), then incubated in 
PBG with anti PIAS3 antibody. Biotinylated secondary 
antibody and Streptoavidin conjugated with horseradish 
peroxidase (ABC kit, Vector Labs) were applied to the 
slides,  color  develop  was  achieved  by  using  DAB  kit 
(Vector Labs) following the manufacturer’s instructions. 
All  images  were  captured  at  the  same  light  intensity, 
brightness and contrast.
Human brain tumor rNA
All original brain tumors were obtained from the 
Department  of  Neurosurgery,  The  Cleveland  Clinic 
Foundation, and diagnosed as glioblastoma, astrocytoma 
and oligodendrocytoma by surgical pathology Pieces of 
fresh brain tumors were fast frozen in liquid nitrogen, and 
ground into fine powder for RNA isolation.
Western blot
The U373 cells were lysed in 1% Triton X-100 lysis 
buffer  containing  protease  inhibitors.  Cell  debris  was 
removed by centrifugation. 20 mg of protein from each 
sample was separated on SDS-PAGE gel, transferred to 
PVDF membrane, and blotted with anti PARP antibody. 
Positive bands on the blots were detected by using ECL-
Plus kit (Amersham-Pharmacia) following manufacturer’s 
instruction.
RT-PCR amplification of PIAS3 mRNA sequences
Total RNA extracted from normal white matter and 
brain tumors was reverse transcribed to cDNA. PIAS3’s 
coding sequences from nucleotide 1 to 861 was amplified 
by 35 cycles of denaturing at 95ΟC for 1’, annealing at 
55ΟC for 1’, and polymerization at 72ΟC for 1’30”. A 516 
bp β-actin fragment was also amplified for quality control.
Measurement of glioma cell motility
Cell  migration  was  measured  by  the  ‘artificial 
wound’ method as described [8]. Confluent U373 cells in 
12-well tissue culture plates were cut-lift (wound) with a 
razor and 50 pfu/cell Ad/PIAS3 was added to the medium 
for infection. Control cells were infected with Ad/GFP 
at  the  same  concentration. A  digital  camera  on  phase-
contrast microscope was used to capture images of cell 
migration. In each well, three random fields were chosen 
to count the number of cells that crossed the origin line 
and to calculate the median distance the cells migrated. 
The data from triplicate wells were expressed as the mean 
and standard error of the number of migrating cells, as 
well as the median distance. All experiments were done at 
least three times.
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